A staff member of Sinovac works on the COVID-19 vaccine production line in Beijing, on July 8, 2021. (PHOTO / XINHUA)
Sinovac Biotech Ltd, a biopharmaceutical product provider in China, officially unveiled a vaccine quality research center in Changping district of Beijing on Sunday.
With a total investment of 500 million yuan (US$74 million), the construction of the center has been included both in the key construction projects of Beijing in 2022 and the key medical and health projects in Changping district in 2022.
With a total investment of 500 million yuan (US$74 million), the construction of the center has been included both in the key construction projects of Beijing in 2022
The facility, which is expected to start operations in the fourth quarter of 2023, will be mainly used for the whole-process quality research of vaccines—from raw materials to finished products.
Up to date, Sinovac has supplied vaccines to more than 80 countries and regions. Two of its vaccine products have earned the prequalification certification from the World Health Organization, which means the WHO recognizes the quality, safety and efficacy of the products, while its COVID-19 vaccine has been approved by the organization for emergency use.
ALSO READ: Study: Longer wait for Sinovac booster improves protection
The government of Changping district in Beijing signed a strategic cooperation agreement with Sinovac on July 24, 2022.